Every 10-Q that Danaher Corporation (DHR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DHR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DHR filings page.
Danaher Corporation reported modest growth in early 2026 while preparing a major acquisition. For the quarter ended March 27, 2026, sales rose to $5.95 billion from $5.74 billion, with core sales up 0.5% and currency adding about 3%. Net earnings increased to $1.03 billion, and diluted EPS improved to $1.45 from $1.32, helped by higher sales and lower net interest expense.
The Biotechnology segment led performance with 7% core sales growth and a margin expansion to 29.7%, driven by stronger bioprocessing consumables demand. Life Sciences posted slight core growth and margin improvement, while Diagnostics core sales fell 4% as respiratory testing softened and China pricing pressure weighed, reducing its margin to 27.9%.
Danaher agreed to acquire Masimo Corporation, a patient monitoring and pulse oximetry specialist with 2025 revenue of about $1.5 billion, for roughly $9.9 billion in cash, to be included in Diagnostics. To support funding and liquidity, the company added a $5.0 billion 364‑day revolving credit facility and increased euro commercial paper, while also repaying €1.3 billion of 2026 Biopharma Euronotes. Operating cash flow was strong at $1.32 billion, lifting cash and equivalents to $5.70 billion.
Danaher Corporation reported Q3 results with sales of $6,053 million, up from $5,798 million a year ago. Operating profit rose to $1,154 million and net earnings increased to $908 million, delivering diluted EPS of $1.27 versus $1.12.
Year-to-date, sales reached $17,730 million and net earnings were $2,417 million. The effective tax rate was 15.6% for the quarter. By segment in Q3, Biotechnology generated $1,798 million of sales, Life Sciences $1,792 million, and Diagnostics $2,463 million. The company recorded $101 million of impairments in the quarter, primarily in Biotechnology and Diagnostics.
Cash from operating activities was $4,299 million for the nine-month period. Danaher repurchased $3,088 million of common stock year-to-date and repaid $500 million of notes on September 15, 2025. After quarter-end, it issued CHF 1,250 million of Swiss franc bonds for general corporate purposes. Shares outstanding were 706,349,563 as of October 16, 2025.